Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which is in phase I/II clinical trial for the treatment of Basal thumb osteoarthritis; and ENX-CL-06-001 to treat Psoriatic arthritis and is in phase I/II clinical trial. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Ness Ziona, Israel.
Metrics to compare | ENLV | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipENLVPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.8x | −3.7x | −0.5x | |
PEG Ratio | −0.04 | −0.03 | 0.00 | |
Price/Book | 1.3x | 2.4x | 2.6x | |
Price / LTM Sales | - | 7.2x | 3.0x | |
Upside (Analyst Target) | - | 620.3% | 52.5% | |
Fair Value Upside | Unlock | 17.7% | 8.7% | Unlock |